Measure, Share, Improve
For Novo Nordisk, a global healthcare company committed to changing the way diabetes is viewed and treated, finding solutions begins with applying a mindset of Measure, Share, Improve. We believe it’s essential to measure the state of diabetes, share what we’ve learned, and work to improve the status quo.
Novo Nordisk conducts research that helps describe and measure the problems and challenges the U.S. faces in diabetes.
- "The Economic Burden of Elevated Blood Glucose Levels in 2012: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes, and Prediabetes,"1 published in the December 2014 issue of Diabetes Care, reports that the total cost of diabetes in 2012 was $322 billion, up 48% from $218 billion in 2007.1
- "United States' Diabetes Crisis: Today and Future Trends"2 contains data that show how diabetes prevalence and costs compare in 2010 with projections for 2025.
- "The US Preventive Services Task Force (USPSTF) Should Consider a Broader Evidence Base in Updating Its Diabetes Screening Guidelines"3 reviews the literature and provides arguments for why and how the USPSTF could change its approach to reviewing the evidence for diabetes screening.
- "Detecting type 2 diabetes and prediabetes among asymptomatic adults in the United States: modeling American Diabetes Association versus US Preventive Services Task Force diabetes screening guidelines"4 is a modeling study that assessed the relative ability of USPSTF and ADA screening recommendations to identify adults with undiagnosed diabetes and prediabetes.
- Additionally, Novo Nordisk commissioned a second phase of the study, cited above, that used a micro-simulation model to simulate future health and economic outcomes in comparing early versus delayed diagnosis and treatment for diabetes and prediabetes, under both ADA and USPSTF screening scenarios. This research has been reviewed and accepted for publication by a major peer reviewed journal and should be published in the fourth quarter of 2014.
- Novo Nordisk commissioned research to identify the total cost of diagnosed diabetes, undiagnosed diabetes, prediabetes, and gestational diabetes mellitus. This research builds upon work commissioned by the American Diabetes Association, which found the cost of diagnosed diabetes alone to be $245 billion in 2012. A manuscript of research results has been accepted by a major peer-reviewed journal and publication is expected in late 2014 or early 2015.
- Novo Nordisk has commissioned research that is using “Rule of Halves” (ROH) theory5 to examine the need for better diabetes screening, diagnosis, treatment, and patient outcomes. We believe the results of this research could help policymakers, legislators, payers, and health care providers gain a better understanding of how effectively diabetes and prediabetes are being treated in America.
- Novo Nordisk previously commissioned work that measured the state of diabetes and prediabetes in America from the economic, clinical, and societal perspectives.
Sharing and Engaging with Government Stakeholders
Novo Nordisk’s Government Affairs and Public Policy teams share Barometer materials and tools in their daily efforts to raise diabetes higher on the national agenda. Barometer data help inform meetings with key stakeholders in Washington, D.C., including Members of Congress and their staffs, and executives at federal government agencies. They also use Barometer data in briefings held on Capitol Hill and as part of comments submitted to federal agencies concerning proposed policies or regulations.
Visit the Diabetes Policy section to learn about our key strategies for changing the way America tackles major challenges posed by diabetes.
Diabetes Advocacy AllianceTM (DAA)
Along with American Association of Diabetes Educators (AADE) and the American Diabetes Association (ADA), Novo Nordisk is a co-chair and founding partner of the Diabetes Advocacy AllianceTM (DAA). The DAA is a coalition with 20 members that represent patient, professional and trade associations, other nonprofit organizations, and corporations, united in the desire to change the way diabetes is viewed and treated in America.6
The newest DAA member is the American Medical Association.
The members of the DAA collaborate in sharing information to educate legislators and policymakers about:
- The enormous challenges that diabetes and prediabetes pose to U.S. health and prosperity; and
- How legislation and public policy can help change the course of significant growth in the population of people with type 2 diabetes, and the complications associated with all types of diabetes that are expected in the coming decades.
Learn more about the initiatives and activities of the Diabetes Advocacy Alliance.
When it comes to shaping public policy and legislation that would improve outcomes for people with diabetes and prediabetes, Novo Nordisk works on its own and in collaboration with members of the DAA.
We use data and information from Barometer research in developing strategies, activities and messages for interacting with policymakers, legislators, payers, and other key stakeholders. We inform them of the value of diabetes screening, prevention, early intervention, treatment, and improved control.
Helping Patients and the Public "Act for Diabetes"
Novo Nordisk Government Affairs uses messages, data, information, and tools from Barometer initiatives to inform the development of specific pieces of legislation that are designed to improve the lives of people with diabetes and prediabetes. To move such legislation along the path to passage, Members of Congress must hear directly about how serious diabetes and prediabetes are from the people who elected them, and why certain legislation is essential.
To help facilitate this process, Novo Nordisk Government Affairs has created an online, interactive tool called “Act for Diabetes.” It provides background information about important diabetes issues and allows people to easily send messages to their elected officials.
Learn about legislation that Novo Nordisk and members of the Diabetes Advocacy Alliance are supporting by visiting Act for Diabetes. Also, you can easily identify and contact your elected officials and ask for their support via the Act for Diabetes website.
Supporting Prevention of Type 2 Diabetes
Novo Nordisk has been an active supporter of programs designed to help at-risk older adults prevent the onset of type 2 diabetes.
We’ve supported the YMCA of the USA in its efforts to roll out the National Diabetes Prevention Program (National DPP) across the country. Specifically, we have given grants to support demonstration projects designed to better understand the processes involved in creating awareness, recruiting, and enrolling adults aged 65 and older in Medicare in community-based diabetes prevention programs. To this end, we’ve worked with the YMCA in pilot programs in Atlanta, Georgia; Phoenix, Arizona; and Louisville and Lexington in Kentucky.
Through our support of the Medicare Diabetes Screening Project (MDSP), we’ve provided grants to dozens of community-based organizations interested in promoting awareness of the benefits that Medicare offers for diabetes screening.